Korro Bio, Inc. Payments to Acquire Marketable Securities
Korro Bio, Inc. (KRRO) reported Payments to Acquire Marketable Securities of $75.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Korro Bio, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $29.86M, a 167.57% increase year-over-year.
- Korro Bio, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $45.22M.
- Korro Bio, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Korro Bio, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $15.03M, a 30.75% decline year-over-year.
- Korro Bio, Inc. payments to acquire marketable securities for fiscal 2025 was $26.19M, a 82.10% decline from fiscal 2024.
- Korro Bio, Inc. payments to acquire marketable securities for fiscal 2024 was $146.34M.
- Korro Bio, Inc. payments to acquire marketable securities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Korro Bio, Inc. payments to acquire marketable securities for fiscal 2022 was $54.22M, a 41.35% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 9 month as first filed | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $29.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $75.08M 10-Q · filed 2026-08-06 | $75.08M derived: sum of 3 quarters · filed 2026-08-06 | $90.11M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $45.22M 10-Q · filed 2026-05-07 | $45.22M derived: sum of 2 quarters · filed 2026-05-07 | $60.25M derived: sum of 3 quarters · filed 2026-05-07 | $71.41M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $15.03M derived: sum of 2 quarters · filed 2026-03-12 | $26.19M derived: sum of 3 quarters · filed 2026-08-06 | $26.19M 10-K · filed 2026-03-12 | ||
| 2025-09-30 | $15.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $26.19M derived: sum of 2 quarters · filed 2026-08-06 | $26.19M 10-Q · filed 2025-11-12 | $54.40M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $11.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.16M 10-Q · filed 2026-08-06 | $39.37M derived: sum of 3 quarters · filed 2026-08-06 | $61.07M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $28.21M derived: sum of 2 quarters · filed 2026-05-07 | $49.91M derived: sum of 3 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $28.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $49.91M derived: sum of 2 quarters · filed 2026-03-12 | $146.34M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $21.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $118.13M 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | $96.43M 10-Q · filed 2025-08-12 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $0.00 derived: sum of 2 quarters · filed 2025-03-18 | -$1.98M derived: sum of 3 quarters · filed 2025-03-18 | $0.00 10-K · filed 2025-03-18 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.98M derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $1.98M 10-Q · filed 2023-11-02 | $7.31M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $1.98M 10-Q · filed 2023-08-10 | $7.31M derived: sum of 3 quarters · filed 2024-08-13 | $16.11M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $1.98M 10-Q · filed 2023-05-12 | $9.29M derived: sum of 2 quarters · filed 2023-05-12 | $18.09M derived: sum of 3 quarters · filed 2023-11-02 | $35.41M derived: sum of 4 quarters · filed 2023-11-02 | ||
| 2022-12-31 | $7.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $16.11M derived: sum of 2 quarters · filed 2023-11-02 | $33.44M derived: sum of 3 quarters · filed 2023-11-02 | $54.22M 10-K · filed 2023-03-10 | ||
| 2022-09-30 | $8.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $26.13M derived: sum of 2 quarters · filed 2023-11-02 | $46.91M 10-Q · filed 2023-11-02 | $73.13M derived: sum of 4 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $17.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $38.11M 10-Q · filed 2023-08-10 | $64.33M derived: sum of 3 quarters · filed 2023-08-10 | $87.53M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $20.79M 10-Q · filed 2023-05-12 | $47.01M derived: sum of 2 quarters · filed 2023-05-12 | $70.21M derived: sum of 3 quarters · filed 2023-05-12 | $87.56M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $26.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $49.42M derived: sum of 2 quarters · filed 2023-03-10 | $66.78M derived: sum of 3 quarters · filed 2023-03-10 | $92.44M 10-K · filed 2023-03-10 | ||
| 2021-09-30 | $23.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $40.56M derived: sum of 2 quarters · filed 2022-11-08 | $66.23M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $17.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $43.02M 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | $25.67M 10-Q · filed 2022-05-04 | |||||
| 2020-12-31 | $26.34M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |